Ito Fumito, Evans Sharon S
Center for Immunotherapy, Roswell Park Cancer Institute, Buffalo, New York, USA.
Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, New York, USA.
J Vaccines Vaccin. 2016 Apr;7(2). doi: 10.4172/2157-7560.1000310. Epub 2016 Mar 9.
A lack of effective immune response against cancer is one of the major risk factors for developing local recurrence and distant metastases after curative resectional surgery. Prior studies revealed that systemic antitumor immunity is elicited by radiofrequency ablation (RFA) of tumor lesions, which is mainly considered a palliative procedure for unresectable tumors or for inoperable patients. Recently, we discovered an oncological benefit that depends on the adaptive arm of the antitumor immune response when RFA is performed in a neoadjuvant setting prior to surgical resection in preclinical murine models.
缺乏针对癌症的有效免疫反应是根治性切除术后发生局部复发和远处转移的主要风险因素之一。先前的研究表明,肿瘤病灶的射频消融(RFA)可引发全身抗肿瘤免疫,而RFA主要被视为对不可切除肿瘤或无法手术的患者的一种姑息性治疗手段。最近,我们发现在临床前小鼠模型中,在手术切除前以新辅助方式进行RFA时,存在一种依赖于抗肿瘤免疫反应适应性分支的肿瘤学益处。